Financial results for the period ended March 31, 2026
As filed · Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
EarningsMajormateriality 80 out of 100
What happened
FactBliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. The Audited Standalone and Consolidated Financial Results for the quarter and year ended. 1 Rupee per equity share on face value of Rs. 1/-.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
Evidence
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%